Journals / Turkish Journal of Hematology / 2010 / Cilt: 27 - Sayı: 2

Allogeneik hematopoietik hücre nakli sonrası sklerodermatoz tip graft-versus- host hastalığının klinik yönleri

Clinical aspects of sclerodermatous type graft-versus-host disease after allogeneic hematopoietic cell transplantation

Pages
91–98
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although most lesions do not disappear in the course of the disease, most patients have a good prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to evaluate the clinical features of sclerodermatous chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (AHSCT).
📊
Key Findings & Data:Materials and Methods: We retrospectively analyzed 423 patients who underwent AHSCT.
💡
Conclusion & Impact:Although most lesions do not disappear in the course of the disease, most patients have a good prognosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to evaluate the clinical features of sclerodermatous chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (AHSCT). Materials and Methods: We retrospectively analyzed 423 patients who underwent AHSCT. We assessed age, sex, pretransplant diagnosis, conditioning regimen, GVHD prophylaxis, and occurrence of acute GVHD (aGVHD), chronic lichenoid and chronic systemic GVHD, and clinical properties of sclerodermatous GVHD. Results: Sclerotic skin lesions developed in 22 patients after a mean of 752±647 days (median 480). aGVHD appeared in 17 patients, with hepatic involvement in 2, gastrointestinal tract involvement in 2 and skin involvement in 13 of these patients. Extensive chronic GVHD (liver, pulmonary, skin and oral mucosa) developed in 12 patients. Sclerosis was generalized in 19 patients (86.4%) and localized in 3 patients (13.6%). Leopard skin eruption appeared in 8 (36.4%) of the 19 patients with generalized sclerodermatous changes. In most cases, sclerotic lesions appeared on the trunk, and distal parts of the extremities were spared. Eight patients (36.4%) progressed from lichenoid to sclerodermatous lesions, 2 (9.1%) with lichenoid and sclerodermatous phases together and 12 (55.5%) with de novo sclerodermatous lesions. Five patients died because of late transplant-related complications. Conclusion: Sclerodermatous GVHD has a late onset and may be quite disabling. Unlike scleroderma, acral involvement is seen rarely. Although most lesions do not disappear in the course of the disease, most patients have a good prognosis.

Özet

Amaç: Allogeneik hematopoietik kök hücre nakli (Allo-HKHN) sonrası gelişen sklerodermatoz graft-versus-host hastalığının (GVHH) klinik özelliklerinin değerlendirilmesi amaçlanmıştır. Yöntem ve Gereçler: Allo-HKHN yapılan 423 hasta retrospektif olarak analiz edilmiştir. Olguların yaş, cinsiyet, transplantasyon öncesi tanıları, hazırlık rejimleri, GVHH proflaksileri, akut GVHH ve/veya kronik likenoid ve kronik sistemik GVHH mevcudiyeti ve gelişen sklerodermatoz GVHH’nın klinik özellikleri değerlendirilmiştir. Bulgular: Sklerotik lezyonlar 22 hastada ortalama 752±647 gün (ortanca 480) sonra gelişmiştir. Akut GVHH 17 hastada gelişirken, bunların 2’sinde karaciğer, 2’sinde gastrointestinal sistem ve 14’ünde deri tutulumu gözlenmiştir. Yaygın kronik GVHH (karaciğer, akciğer, deri ve oral mukoza) 12 hastada gelişmiştir. Skleroz 19 hastada (%86.4) jeneralize, 3 hastada (%13.6) lokalizeydi. Jeneralize sklerodermatoz değişiklikler izlenen 19 hastanın 8’inde (%36.4) leopar derisi görünümü mevcuttu. Olguların çoğunda sklerotik lezyonlar gövdede yerleşirken, ekstremitelerin distali etkilenmemiştir. Olguların 8’i likenoid GVHH’dan sklerodermatoz GVHH’ye dönüşürken, 2’sinde her iki faz bir arada ve 12’sinde sklerodermatoz GVHH denovo olarak gelişmiştir. Beş olgu transplantasyonla ilişkili geç komplikasyonlar nedeniyle vefat etmiştir Sonuç: Sklerodermatoz GVHH geç başlangıçlı ve hastalar için oldukça sıkıntı oluşturabilen bir tablodur. Sklerodermanın aksine akral tutulum nadiren görülür. Lezyonlar hastalık seyri boyunca kaybolmamakla birlikte pek çok olguda prognoz iyidir.

🔖

Cite This Article

ŞANLI, H., AKAY, B. N., SOYDAN, E., KOÇYİĞİT, P., ARAT, M., İLHAN, O. (2010). Allogeneik hematopoietik hücre nakli sonrası sklerodermatoz tip graft-versus- host hastalığının klinik yönleri. Turkish Journal of Hematology, Cilt: 27 - Sayı: 2, 91–98. https://ajindex.com/articles/413383

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Graham Brown RAC, Sarkany I. Scleroderma like changes due to chronic graft versus host disease. Clin Exp Dermatol 1983;8:531-8
  2. Peñas PF, Jones-Caballero M, Aragüés M, Fernández-Herrera J, Fraga J, García-Díez A. Arch Dermatol. 2002 Jul;138(7):924-34. PMID: 12071820 3. Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, Wechsler J, André C, Touraine R, Revuz J. Sclerodermatous chronic graft-versus-host disease: analysis of seven cases. J Am Acad Dermatol 1992;26:49-55
  3. Shulman HM, Sale GE, Lerner KG, Barker EA, Weiden PL, Sullivan K, Gallucci B, Thomas ED, Storb R. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978;91:545-70
  4. Skert C, Patriarca F, Sperotto A, Cerno M, Filì C, Zaja F, Stocchi R, Geromin A, Damiani D, Fanin R. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006;91:258 61
  5. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol 1998;134:602-12
  6. Johnson ML, Farmer ER. Graft versus host reactions in dermatology. J Am Acad Dermatol 1998;38:369-92
  7. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus develop ment project on criteria for clinical trials in chronic graft-versus host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56
  8. Magro CM, Kerns MJ, Votava H, Vasil KE, Dyrsen ME, Morrison CD. Early-onset lichenoid graft-vs.-host disease: a unique variant of acute graft-vs.-host disease occurring in peripheral bloodstem cell transplant recipients. J Cutan Pathol. 2009 Oct 15. [Epub ahead of print] 10. Fleming JN, Shulman HM, Nash RA, Johnson PY, Wight TN, Gown A, Schwartz SM. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One. 2009;4:e6203
  9. Roujeau JC, Revuz J, Touraine R. Graft versus host reactions. In: Rook A, Savin J, editors. Recent Advances in Dermatology. Vol 5. New York: Churchill Livingstone Inc, 1980: 131-57
  10. Belch J. Raynoud’s phenomenon: its relevance to scleroderma. Ann Rheum Dis 1991;50:839-45.